- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07756307
Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis (ESWT)
9 de agosto de 2026 atualizado por: Huang ShihWei, Taipei Medical University WanFang Hospital
Effectiveness of Ultrasound-Guided Extracorporeal Shock Wave Therapy for Calcific Tendinitis of the Shoulder: A Randomized Double-Blind Controlled Trial
Calcific tendinitis of the shoulder is a debilitating musculoskeletal condition that significantly impacts the working-age population, typically those between 30 and 60 years of age.
Accounting for approximately 7- 17% of shoulder pain complaints, it is characterized by the pathological deposition of calcium hydroxyapatite crystals within the rotator cuff tendons, most notably the supraspinatus.
The progression of the disease, particularly during the resorptive phase described in Uhthoff's cycle, is associated with a dramatic increase in intratendinous pressure and severe inflammatory pain, leading to substantial functional impairment and socioeconomic burden.
While Extracorporeal Shock Wave Therapy (ESWT) is a well established non-invasive modality known to promote calcific resorption via cavitation effects and mechanotransduction-induced neovascularization, its clinical efficacy remains highly variable across current literature, with success rates ranging widely from 47% to 87%.
This inconsistency is largely attributed to the limitations inherent in conventional "blind" or landmark-based targeting techniques.
Given that calcific deposits are often small, deeply situated, or obscured by the acromion, palpation-guided targeting is frequently unreliable, resulting in suboptimal energy delivery to the pathology and potential collateral damage to surrounding healthy tissues.
This one-year research project aims to evaluate the superior efficacy of "Real-time Ultrasound-Guided" ESWT compared to conventional methods.
The investigators propose a prospective, randomized, double-blind, controlled trial (RCT) that will recruit 60 patients with confirmed calcific tendinitis.
Participants will be stratified by Gärtner classification (Type I-III) to ensure balanced morphological distribution and then randomized into either an experimental group receiving Ultrasound-Guided Focused ESWT or a control group receiving Landmark-based/Sham ESWT.
The study incorporates rigorous methodology, including a priori power analysis for sample size estimation, strict allocation concealment, and assessor blinding.
Outcomes will be assessed at baseline, 4, and 12 weeks post-treatment.
Primary outcomes include the Constant-Murley Score (CMS) and Visual Analog Scale (VAS), while secondary outcomes involve quantitative ultrasound analysis using ImageJ software to measure the reduction in calcific deposit volume and assess tendon integrity.
The investigators hypothesize that the integration of realtime ultrasound guidance will significantly enhance therapeutic precision, leading to higher rates of calcific resorption and functional recovery.
The findings are expected to provide high-level evidence to standardize ESWT protocols, thereby advancing the implementation of precision medicine in the field of physical and rehabilitation medicine.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
60
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Shih-Wei Huang, MD
- Número de telefone: +886970747556
- E-mail: shihwei@tmu.edu.tw
Locais de estudo
-
-
Taipei
-
Taipei, Taipei, Taiwan, 116
- Recrutamento
- Wan Fang Hospital, Taipei Medical University
-
Contato:
- Shih-Wei Huang
- Número de telefone: 0970747556
- E-mail: shihwei@tmu.edu.tw
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Age between 20 and 70 years
- Unilateral calcific tendinitis of the shoulder confirmed by clinical physical examination, including a positive Neer's impingement test
- Symptom duration of more than 3 months
- Imaging (radiography and/or high-resolution ultrasound) demonstrating a calcific deposit within a rotator cuff tendon with a maximal diameter greater than 5 mm
- Baseline self-reported pain intensity greater than 4 on the Visual Analog Scale (VAS, 0-10)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Concomitant full-thickness rotator cuff tear
- History of fracture or surgery involving the ipsilateral shoulder
- Coagulopathy, or anticoagulant therapy that cannot be safely discontinued
- Pregnancy or breastfeeding
- Malignancy, particularly involving or adjacent to the shoulder region
- Local infection or skin lesion at the intended treatment site
- Injection therapy to the ipsilateral shoulder within the preceding 6 weeks
- Any other condition that, in the judgment of the investigator, makes the participant unsuitable for participation in the trial
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Ultrasound localization ESWT
Ultrasound image guided the depth and location of calcification point, Perform ESWT for calcific tendonitis of shoulder
|
Use ultrasound guided localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
|
Comparador Ativo: Palpation localization ESWT
Palpation and depends the feedback of participants localization of ESWT points
|
Use palpation localization of calcific tendonitis of shoulder and then perform Extracorporeal Shock Wave Therapy, ESWT 0.12 to 0.25 mJ/mm 6000 times
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Constant-Murley Score (CMS)
Prazo: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
The Constant-Murley Score is a clinician-administered instrument assessing shoulder function across four domains: pain (15 points), activities of daily living (20 points), range of motion (40 points), and strength (25 points), for a total score of 0-100.
Higher scores indicate better shoulder function.
The measure compares real-time high-resolution ultrasound-guided focused ESWT (experimental) with X-ray plus palpation-guided focused ESWT (control) for calcific tendinitis of the shoulder.
Assessed at baseline, Week 4, and Week 12; change from baseline is reported.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change in Pain Visual Analog Scale (VAS)
Prazo: Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
Pain intensity is self-reported on a 0-10 Visual Analog Scale, where 0 = no pain and 10 = worst imaginable pain.
Ratings are collected for pain at rest, pain with activity, night pain, and average pain over the past week.
Higher scores indicate greater pain.
Change from baseline is compared between the ultrasound-guided ESWT and landmark (X-ray + palpation)-guided ESWT groups.
Assessed at baseline, Week 4, and Week 12.
|
Baseline, Week 4, and Week 12 after the start of treatment (primary endpoint at Week 12)
|
|
Change from Baseline in Shoulder Pain and Disability Index (SPADI)
Prazo: Baseline, Week 4, Week 12
|
Patient-reported questionnaire comprising a 5-item pain subscale and an 8-item disability subscale, each item scored 0-10.
Subscale and total scores are expressed as percentages (0-100%), with higher scores indicating greater pain and disability.
|
Baseline, Week 4, Week 12
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Calcific Deposit Resorption Rate
Prazo: Baseline, Week 4, Week 12
|
Calcific deposit dimensions (long axis, short axis, area, and estimated volume) are quantified from ultrasound images using ImageJ software.
Percentage volume reduction from baseline is calculated.
Resorption is additionally categorized as complete, partial (>50%), partial (<50%), unchanged, or increased.
|
Baseline, Week 4, Week 12
|
|
Change from Baseline in Shoulder Range of Motion (ROM)
Prazo: Baseline, Week 4, Week 12
|
Active and passive range of motion measured in degrees with a goniometer for forward flexion, abduction, external rotation at 90° abduction, and internal rotation at 90° abduction.
|
Baseline, Week 4, Week 12
|
|
Tendon Structural Integrity on Ultrasound
Prazo: Baseline, Week 4, Week 12
|
Supraspinatus (or affected) tendon integrity graded on high-resolution ultrasound as intact, partial-thickness tear, or full-thickness tear.
Tendon thickness is recorded in millimeters.
|
Baseline, Week 4, Week 12
|
|
Patient Global Impression of Change (PGIC)
Prazo: Week 4, Week 12
|
Single-item 7-point scale ranging from 1 (very much improved) to 7 (very much worse), capturing the participant's overall perceived change since starting treatment.
|
Week 4, Week 12
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
30 de junho de 2026
Conclusão Primária (Estimado)
30 de abril de 2027
Conclusão do estudo (Estimado)
31 de agosto de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
5 de agosto de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
5 de agosto de 2026
Primeira postagem (Real)
10 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
12 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
9 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- N202604139
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Descrição do plano IPD
De-identified individual participant data (IPD) that underlie the results reported in the publication (including text, tables, figures, and appendices) will be shared.
This includes baseline characteristics, intervention adherence, and primary and secondary outcome measures.
Additionally, the study protocol, statistical analysis plan (SAP), and data dictionary will be made available.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .